U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C26H37NO3
Molecular Weight 411.5779
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FESOTERODINE

SMILES

CC(C)C(=O)Oc1ccc(cc1[C@]([H])(CCN(C(C)C)C(C)C)c2ccccc2)CO

InChI

InChIKey=DCCSDBARQIPTGU-HSZRJFAPSA-N
InChI=1S/C26H37NO3/c1-18(2)26(29)30-25-13-12-21(17-28)16-24(25)23(22-10-8-7-9-11-22)14-15-27(19(3)4)20(5)6/h7-13,16,18-20,23,28H,14-15,17H2,1-6H3/t23-/m1/s1

HIDE SMILES / InChI

Description
Curator's Comment:: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/18279452

Fesoterodine (trade name Toviaz) is a prodrug of 5-hydroxymethyl tolterodine, which is also the active metabolite of tolterodine. Fesoterodine and its active metabolites are nonsubtype selective, competitive antagonists of human muscarinic receptors, but 5-hydroxymethyl tolterodine has greater potency than the parent compound. A prodrug approach was necessary for systemic bioavailability of 5-hydroxymethyl tolterodine after oral administration. Fesoterodine was originated by Schwarz Pharma (later a subsidiary of UCB) and is being developed by Pfizer for the treatment of overactive bladder and urinary urge incontinence. The agent is launched in several countries for the treatment of overactive bladder, including the US, Japan, Canada, Europe and Asia.

CNS Activity

Curator's Comment:: Fesoterodine is a substrate for permeability-glycoprotein (P-gp) and, therefore, is actively transported away from the brain.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
TOVIAZ

Approved Use

Toviaz is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

Launch Date

1.22532476E12
Primary
TOVIAZ

Approved Use

Toviaz® is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Toviaz is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

Launch Date

1.22541126E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.89 ng/mL
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
5-HYDROXYMETHYL TOLTERODINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7.31 h
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
5-HYDROXYMETHYL TOLTERODINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
50%
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
5-HYDROXYMETHYL TOLTERODINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Other AEs: Coronary artery occlusion, Influenza...
Other AEs:
Coronary artery occlusion (serious, 1 patient)
Influenza (serious, 1 patient)
Urosepsis (serious, 1 patient)
Fall (serious, 1 patient)
Femur fracture (serious, 1 patient)
Haemarthrosis (serious, 1 patient)
Muscular weakness (serious, 1 patient)
Osteoarthritis (serious, 1 patient)
Bradycardia (below serious, 1 patient)
Cardiac failure congestive (below serious, 1 patient)
Ventricular extrasystoles (below serious, 1 patient)
Dry eye (below serious, 4 patients)
Discharge eye (below serious, 1 patient)
Eye haemorrhage (below serious, 1 patient)
Eye oedema (below serious, 1 patient)
Eye swelling (below serious, 1 patient)
Vitreous floaters (below serious, 1 patient)
Abdominal discomfort (below serious, 1 patient)
Abdominal distension (below serious, 2 patients)
Constipation (below serious, 31 patient)
Diarrhoea (below serious, 8 patients)
Dry mouth (below serious, 66 patients)
Dyspepsia (below serious, 7 patients)
Faecal incontinence (below serious, 1 patient)
Flatulence (below serious, 2 patients)
Gastrooesophageal reflux disease (below serious, 3 patients)
Haemorrhoids (below serious, 1 patient)
Hiatus hernia (below serious, 1 patient)
Nausea (below serious, 5 patients)
Tongue dry (below serious, 1 patient)
Fatigue (below serious, 8 patients)
Local swelling (below serious, 1 patient)
Oedema (below serious, 1 patient)
Therapeutic response unexpected (below serious, 1 patient)
Candidiasis (below serious, 1 patient)
Diverticulitis (below serious, 1 patient)
Herpes simplex (below serious, 1 patient)
Herpes zoster ophthalmic (below serious, 1 patient)
Oral herpes (below serious, 1 patient)
Pneumonia viral (below serious, 1 patient)
Sinusitis (below serious, 5 patients)
Tinea pedis (below serious, 1 patient)
Tooth abscess (below serious, 1 patient)
Vulvovaginal candidiasis (below serious, 1 patient)
Arthropod bite (below serious, 1 patient)
Contusion (below serious, 3 patients)
Laceration (below serious, 1 patient)
Post procedural haematoma (below serious, 1 patient)
Skeletal injury (below serious, 2 patients)
Blood glucose increased (below serious, 1 patient)
Blood pressure increased (below serious, 2 patients)
Blood uric acid increased (below serious, 1 patient)
International normalised ratio increased (below serious, 1 patient)
Residual urine volume increased (below serious, 1 patient)
Weight increased (below serious, 1 patient)
Gout (below serious, 2 patients)
Type 2 diabetes mellitus (below serious, 1 patient)
Back pain (below serious, 4 patients)
Bursitis (below serious, 1 patient)
Intervertebral disc degeneration (below serious, 1 patient)
Musculoskeletal chest pain (below serious, 1 patient)
Musculoskeletal pain (below serious, 2 patients)
Osteoporosis (below serious, 1 patient)
Trigger finger (below serious, 1 patient)
Skin cancer (below serious, 1 patient)
Diabetic neuropathy (below serious, 1 patient)
Dizziness (below serious, 3 patients)
Headache (below serious, 7 patients)
Hypersomnia (below serious, 1 patient)
Memory impairment (below serious, 2 patients)
Migraine (below serious, 1 patient)
Sinus headache (below serious, 1 patient)
Tremor (below serious, 1 patient)
Confusional state (below serious, 1 patient)
Depression (below serious, 1 patient)
Sleep disorder (below serious, 1 patient)
Dysuria (below serious, 4 patients)
Nephrolithiasis (below serious, 1 patient)
Urinary hesitation (below serious, 1 patient)
Urinary retention (below serious, 9 patients)
Urine odour abnormal (below serious, 1 patient)
Haemorrhage vaginal (below serious, 1 patient)
Asthma (below serious, 1 patient)
Bronchospasm (below serious, 1 patient)
Chronic obstructive pulmonary disease (below serious, 2 patients)
Cough (below serious, 7 patients)
Dry throat (below serious, 5 patients)
Dysphonia (below serious, 1 patient)
Dyspnoea exertional (below serious, 1 patient)
Epistaxis (below serious, 1 patient)
Nasal dryness (below serious, 1 patient)
Oropharyngeal pain (below serious, 2 patients)
Allergic rhinitis (below serious, 1 patient)
Sinus congestion (below serious, 2 patients)
Blister (below serious, 1 patient)
Ingrowing nail (below serious, 1 patient)
Onychoclasis (below serious, 1 patient)
Pruritus (below serious, 2 patients)
Generalised pruritus (below serious, 1 patient)
Urticaria (below serious, 1 patient)
Flushing (below serious, 1 patient)
Sources:
28 mg 1 times / day multiple, oral
Highest studied dose
Dose: 28 mg, 1 times / day
Route: oral
Route: multiple
Dose: 28 mg, 1 times / day
Sources: Page: p.9, 18
unhealthy
Health Status: unhealthy
Condition: Overactive bladder
Sources: Page: p.9, 18
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources: Page: p.4
unhealthy
n = 785
Health Status: unhealthy
Condition: Overactive bladder
Population Size: 785
Sources: Page: p.4
Disc. AE: Dry mouth...
AEs leading to
discontinuation/dose reduction:
Dry mouth (0.8%)
Sources: Page: p.4
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Overactive bladder
Sources: Page: p.1
Disc. AE: Face angioedema, Lip angioedema...
AEs leading to
discontinuation/dose reduction:
Face angioedema
Lip angioedema
Oedema tongue
Angioedema of larynx
Sources: Page: p.1
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
healthy
n = 25
Health Status: healthy
Sex: F
Population Size: 25
Sources:
Other AEs: Dry eye, Abdominal pain...
Other AEs:
Dry eye (below serious, 1 patient)
Abdominal pain (below serious, 2 patients)
Constipation (below serious, 1 patient)
Diarrhoea (below serious, 2 patients)
Dry mouth (below serious, 13 patients)
Dyschezia (below serious, 1 patient)
Oedema peripheral (below serious, 1 patient)
Nasopharyngitis (below serious, 2 patients)
Headache (below serious, 12 patients)
Pollakiuria (below serious, 1 patient)
Dry throat (below serious, 1 patient)
Oropharyngeal pain (below serious, 1 patient)
Sources:
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 322
Health Status: unhealthy
Condition: Urge Urinary Incontinence
Sex: F
Population Size: 322
Sources:
Other AEs: Myocardial infarction, Embolus pulmonary...
Other AEs:
Myocardial infarction (serious, 1 patient)
Embolus pulmonary (serious, 1 patient)
Breast cancer (serious, 1 patient)
Colitis (serious, 1 patient)
Constipation (below serious, 24 patients)
Headache (below serious, 19 patients)
Cold (below serious, 21 patient)
Urinary tract infection (below serious, 17 patients)
Cough (below serious, 10 patients)
Nausea (below serious, 10 patients)
Dyspepsia (below serious, 9 patients)
Sources:
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 471
Health Status: unhealthy
Condition: Overactive Bladder
Sex: M
Population Size: 471
Sources:
Other AEs: Myocardial infarction, Colitis ulcerative...
Other AEs:
Myocardial infarction (serious, 1 patient)
Colitis ulcerative (serious, 1 patient)
Cellulitis staphylococcal (serious, 1 patient)
Genitourinary tract infection (serious, 1 patient)
Intervertebral disc protrusion (serious, 1 patient)
Lung neoplasm malignant (serious, 1 patient)
Transitional cell carcinoma (serious, 1 patient)
Dysuria (serious, 1 patient)
Colic renal (serious, 1 patient)
Testicular torsion (serious, 1 patient)
Orthostatic hypotension (serious, 1 patient)
Abdominal pain (below serious, 6 patients)
Constipation (below serious, 31 patient)
Diarrhoea (below serious, 9 patients)
Dry mouth (below serious, 100 patients)
Dyspepsia (below serious, 9 patients)
Gastritis (below serious, 5 patients)
Nausea (below serious, 6 patients)
Influenza (below serious, 6 patients)
Nasopharyngitis (below serious, 5 patients)
Sinusitis (below serious, 5 patients)
Headache (below serious, 15 patients)
Insomnia (below serious, 9 patients)
Dysuria (below serious, 15 patients)
Urinary retention (below serious, 11 patient)
Erectile dysfunction (below serious, 5 patients)
Sources:
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 679
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 679
Sources:
Other AEs: Anaemia iron deficiency, Hypertensive heart disease...
Other AEs:
Anaemia iron deficiency (serious, 1 patient)
Hypertensive heart disease (serious, 1 patient)
Myocardial ischaemia (serious, 1 patient)
Abdominal pain (serious, 1 patient)
Appendicitis perforated (serious, 1 patient)
Rectal haemorrhage (serious, 1 patient)
Bronchiectasis (serious, 1 patient)
Traumatic brain injury (serious, 1 patient)
Upper limb fracture (serious, 1 patient)
Intervertebral disc protrusion (serious, 1 patient)
Hepatic neoplasm malignant (serious, 1 patient)
Prostate cancer (serious, 1 patient)
Haemorrhage intracranial (serious, 1 patient)
Suicidal behaviour (serious, 1 patient)
Urinary incontinence (serious, 1 patient)
Haemorrhage uterine (serious, 1 patient)
Vision blurred (below serious, 12 patients)
Abdominal pain (below serious, 10 patients)
Abdominal pain upper (below serious, 9 patients)
Constipation (below serious, 37 patients)
Diarrhoea (below serious, 14 patients)
Dry mouth (below serious, 189 patients)
Dyspepsia (below serious, 12 patients)
Vomiting (below serious, 7 patients)
Fatigue (below serious, 12 patients)
Urinary tract infection (below serious, 15 patients)
Dizziness (below serious, 8 patients)
Headache (below serious, 38 patients)
Dysuria (below serious, 4 patients)
Cough (below serious, 8 patients)
Hypertension (below serious, 8 patients)
Sources:
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Other AEs: Septic arthritis staphylococcal, Ankle fracture...
Other AEs:
Septic arthritis staphylococcal (serious, 1 patient)
Ankle fracture (serious, 1 patient)
Fall (serious, 1 patient)
Hip fracture (serious, 1 patient)
Tibia fracture (serious, 1 patient)
Diabetic ketoacidosis (serious, 1 patient)
Lymphoma (serious, 1 patient)
Renal failure acute (serious, 1 patient)
Otorrhoea (below serious, 1 patient)
Hypothyroidism (below serious, 1 patient)
Dry eye (below serious, 9 patients)
Abdominal pain (below serious, 4 patients)
Abdominal pain upper (below serious, 2 patients)
Colitis (below serious, 1 patient)
Constipation (below serious, 15 patients)
Dry mouth (below serious, 98 patients)
Dyspepsia (below serious, 5 patients)
Dysphagia (below serious, 1 patient)
Gastritis (below serious, 1 patient)
Gastrooesophageal reflux disease (below serious, 2 patients)
Haemorrhoids (below serious, 1 patient)
Lip dry (below serious, 1 patient)
Rectal prolapse (below serious, 1 patient)
Stomatitis (below serious, 1 patient)
Asthenia (below serious, 2 patients)
Fatigue (below serious, 5 patients)
Feeling abnormal (below serious, 1 patient)
Gait disturbance (below serious, 1 patient)
Oedema (below serious, 1 patient)
Acute sinusitis (below serious, 1 patient)
Bronchitis (below serious, 1 patient)
Cystitis (below serious, 2 patients)
Diverticulitis (below serious, 1 patient)
Gastroenteritis (below serious, 2 patients)
Gastroenteritis viral (below serious, 1 patient)
Herpes zoster (below serious, 2 patients)
Pharyngitis streptococcal (below serious, 1 patient)
Pneumonia primary atypical (below serious, 1 patient)
Tooth infection (below serious, 1 patient)
Upper respiratory tract infection (below serious, 5 patients)
Urinary tract infection (below serious, 9 patients)
Foot fracture (below serious, 1 patient)
Muscle injury (below serious, 1 patient)
Muscle strain (below serious, 2 patients)
Periorbital haematoma (below serious, 1 patient)
Procedural pain (below serious, 1 patient)
Blood glucose decreased (below serious, 1 patient)
Blood pressure increased (below serious, 2 patients)
Urine output decreased (below serious, 1 patient)
Hyperlipidaemia (below serious, 1 patient)
Hypertriglyceridaemia (below serious, 1 patient)
Pica (below serious, 1 patient)
Polydipsia (below serious, 1 patient)
Type 2 diabetes mellitus (below serious, 2 patients)
Arthralgia (below serious, 3 patients)
Arthritis (below serious, 1 patient)
Bursitis (below serious, 1 patient)
Flank pain (below serious, 3 patients)
Muscle spasms (below serious, 2 patients)
Muscular weakness (below serious, 1 patient)
Myalgia (below serious, 2 patients)
Myositis (below serious, 1 patient)
Neck pain (below serious, 1 patient)
Pain in extremity (below serious, 2 patients)
Basal cell carcinoma (below serious, 1 patient)
Amnesia (below serious, 1 patient)
Dizziness (below serious, 6 patients)
Headache (below serious, 11 patient)
Lethargy (below serious, 1 patient)
Memory impairment (below serious, 1 patient)
Nerve compression (below serious, 1 patient)
Paraesthesia (below serious, 1 patient)
Syncope (below serious, 1 patient)
Tremor (below serious, 1 patient)
Depression (below serious, 2 patients)
Insomnia (below serious, 5 patients)
Dysuria (below serious, 2 patients)
Haematuria (below serious, 1 patient)
Nephrolithiasis (below serious, 1 patient)
Polyuria (below serious, 1 patient)
Urinary hesitation (below serious, 2 patients)
Urinary incontinence (below serious, 1 patient)
Urinary retention (below serious, 3 patients)
Urine flow decreased (below serious, 1 patient)
Chronic obstructive pulmonary disease (below serious, 1 patient)
Dry throat (below serious, 3 patients)
Dysphonia (below serious, 2 patients)
Dyspnoea (below serious, 1 patient)
Epistaxis (below serious, 1 patient)
Nasal congestion (below serious, 3 patients)
Nasal dryness (below serious, 3 patients)
Oropharyngeal pain (below serious, 3 patients)
Rhinorrhoea (below serious, 2 patients)
Throat irritation (below serious, 1 patient)
Dermatitis contact (below serious, 1 patient)
Eczema (below serious, 1 patient)
Generalised pruritus (below serious, 1 patient)
Flushing (below serious, 1 patient)
Hypertension (below serious, 3 patients)
Vision blurred (below serious, 4 patients)
Sources:
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 308
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 308
Sources:
Other AEs: Angina pectoris, Myocardial infarction...
Other AEs:
Angina pectoris (serious, 1 patient)
Myocardial infarction (serious, 1 patient)
Prostate cancer (serious, 1 patient)
Chronic obstructive pulmonary disease (serious, 1 patient)
Hypertension (serious, 1 patient)
Vision blurred (below serious, 3 patients)
Constipation (below serious, 12 patients)
Dry mouth (below serious, 51 patient)
Dyspepsia (below serious, 6 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Abdominal discomfort below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Allergic rhinitis below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Arthropod bite below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Asthma below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Blister below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Blood glucose increased below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Blood uric acid increased below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Bradycardia below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Bronchospasm below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Bursitis below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Candidiasis below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Cardiac failure congestive below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Confusional state below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Depression below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Diabetic neuropathy below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Discharge eye below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Diverticulitis below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Dysphonia below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Dyspnoea exertional below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Epistaxis below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Eye haemorrhage below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Eye oedema below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Eye swelling below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Faecal incontinence below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Flushing below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Generalised pruritus below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Haemorrhage vaginal below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Haemorrhoids below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Herpes simplex below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Herpes zoster ophthalmic below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Hiatus hernia below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Hypersomnia below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Ingrowing nail below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
International normalised ratio increased below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Intervertebral disc degeneration below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Laceration below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Local swelling below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Migraine below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Musculoskeletal chest pain below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Nasal dryness below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Nephrolithiasis below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Oedema below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Onychoclasis below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Oral herpes below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Osteoporosis below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Pneumonia viral below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Post procedural haematoma below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Residual urine volume increased below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Sinus headache below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Skin cancer below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Sleep disorder below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Therapeutic response unexpected below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Tinea pedis below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Tongue dry below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Tooth abscess below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Tremor below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Trigger finger below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Type 2 diabetes mellitus below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Urinary hesitation below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Urine odour abnormal below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Urticaria below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Ventricular extrasystoles below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Vitreous floaters below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Vulvovaginal candidiasis below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Weight increased below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Abdominal distension below serious, 2 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Blood pressure increased below serious, 2 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Chronic obstructive pulmonary disease below serious, 2 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Flatulence below serious, 2 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Gout below serious, 2 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Memory impairment below serious, 2 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Musculoskeletal pain below serious, 2 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Oropharyngeal pain below serious, 2 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Pruritus below serious, 2 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Sinus congestion below serious, 2 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Skeletal injury below serious, 2 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Contusion below serious, 3 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Dizziness below serious, 3 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Gastrooesophageal reflux disease below serious, 3 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Constipation below serious, 31 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Back pain below serious, 4 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Dry eye below serious, 4 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Dysuria below serious, 4 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Dry throat below serious, 5 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Nausea below serious, 5 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Sinusitis below serious, 5 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Dry mouth below serious, 66 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Cough below serious, 7 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Dyspepsia below serious, 7 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Headache below serious, 7 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Diarrhoea below serious, 8 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Fatigue below serious, 8 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Urinary retention below serious, 9 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Coronary artery occlusion serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Fall serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Femur fracture serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Haemarthrosis serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Influenza serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Muscular weakness serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Osteoarthritis serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Urosepsis serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 281
Health Status: unhealthy
Condition: Overactive Bladder
Age Group: adult
Population Size: 281
Sources:
Dry mouth 0.8%
Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources: Page: p.4
unhealthy
n = 785
Health Status: unhealthy
Condition: Overactive bladder
Population Size: 785
Sources: Page: p.4
Angioedema of larynx Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Overactive bladder
Sources: Page: p.1
Face angioedema Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Overactive bladder
Sources: Page: p.1
Lip angioedema Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Overactive bladder
Sources: Page: p.1
Oedema tongue Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Overactive bladder
Sources: Page: p.1
Constipation below serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
healthy
n = 25
Health Status: healthy
Sex: F
Population Size: 25
Sources:
Dry eye below serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
healthy
n = 25
Health Status: healthy
Sex: F
Population Size: 25
Sources:
Dry throat below serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
healthy
n = 25
Health Status: healthy
Sex: F
Population Size: 25
Sources:
Dyschezia below serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
healthy
n = 25
Health Status: healthy
Sex: F
Population Size: 25
Sources:
Oedema peripheral below serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
healthy
n = 25
Health Status: healthy
Sex: F
Population Size: 25
Sources:
Oropharyngeal pain below serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
healthy
n = 25
Health Status: healthy
Sex: F
Population Size: 25
Sources:
Pollakiuria below serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
healthy
n = 25
Health Status: healthy
Sex: F
Population Size: 25
Sources:
Headache below serious, 12 patients
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
healthy
n = 25
Health Status: healthy
Sex: F
Population Size: 25
Sources:
Dry mouth below serious, 13 patients
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
healthy
n = 25
Health Status: healthy
Sex: F
Population Size: 25
Sources:
Abdominal pain below serious, 2 patients
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
healthy
n = 25
Health Status: healthy
Sex: F
Population Size: 25
Sources:
Diarrhoea below serious, 2 patients
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
healthy
n = 25
Health Status: healthy
Sex: F
Population Size: 25
Sources:
Nasopharyngitis below serious, 2 patients
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
healthy
n = 25
Health Status: healthy
Sex: F
Population Size: 25
Sources:
Cough below serious, 10 patients
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 322
Health Status: unhealthy
Condition: Urge Urinary Incontinence
Sex: F
Population Size: 322
Sources:
Nausea below serious, 10 patients
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 322
Health Status: unhealthy
Condition: Urge Urinary Incontinence
Sex: F
Population Size: 322
Sources:
Urinary tract infection below serious, 17 patients
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 322
Health Status: unhealthy
Condition: Urge Urinary Incontinence
Sex: F
Population Size: 322
Sources:
Headache below serious, 19 patients
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 322
Health Status: unhealthy
Condition: Urge Urinary Incontinence
Sex: F
Population Size: 322
Sources:
Cold below serious, 21 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 322
Health Status: unhealthy
Condition: Urge Urinary Incontinence
Sex: F
Population Size: 322
Sources:
Constipation below serious, 24 patients
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 322
Health Status: unhealthy
Condition: Urge Urinary Incontinence
Sex: F
Population Size: 322
Sources:
Dyspepsia below serious, 9 patients
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 322
Health Status: unhealthy
Condition: Urge Urinary Incontinence
Sex: F
Population Size: 322
Sources:
Breast cancer serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 322
Health Status: unhealthy
Condition: Urge Urinary Incontinence
Sex: F
Population Size: 322
Sources:
Colitis serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 322
Health Status: unhealthy
Condition: Urge Urinary Incontinence
Sex: F
Population Size: 322
Sources:
Embolus pulmonary serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 322
Health Status: unhealthy
Condition: Urge Urinary Incontinence
Sex: F
Population Size: 322
Sources:
Myocardial infarction serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 322
Health Status: unhealthy
Condition: Urge Urinary Incontinence
Sex: F
Population Size: 322
Sources:
Dry mouth below serious, 100 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 471
Health Status: unhealthy
Condition: Overactive Bladder
Sex: M
Population Size: 471
Sources:
Urinary retention below serious, 11 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 471
Health Status: unhealthy
Condition: Overactive Bladder
Sex: M
Population Size: 471
Sources:
Dysuria below serious, 15 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 471
Health Status: unhealthy
Condition: Overactive Bladder
Sex: M
Population Size: 471
Sources:
Headache below serious, 15 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 471
Health Status: unhealthy
Condition: Overactive Bladder
Sex: M
Population Size: 471
Sources:
Constipation below serious, 31 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 471
Health Status: unhealthy
Condition: Overactive Bladder
Sex: M
Population Size: 471
Sources:
Erectile dysfunction below serious, 5 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 471
Health Status: unhealthy
Condition: Overactive Bladder
Sex: M
Population Size: 471
Sources:
Gastritis below serious, 5 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 471
Health Status: unhealthy
Condition: Overactive Bladder
Sex: M
Population Size: 471
Sources:
Nasopharyngitis below serious, 5 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 471
Health Status: unhealthy
Condition: Overactive Bladder
Sex: M
Population Size: 471
Sources:
Sinusitis below serious, 5 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 471
Health Status: unhealthy
Condition: Overactive Bladder
Sex: M
Population Size: 471
Sources:
Abdominal pain below serious, 6 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 471
Health Status: unhealthy
Condition: Overactive Bladder
Sex: M
Population Size: 471
Sources:
Influenza below serious, 6 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 471
Health Status: unhealthy
Condition: Overactive Bladder
Sex: M
Population Size: 471
Sources:
Nausea below serious, 6 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 471
Health Status: unhealthy
Condition: Overactive Bladder
Sex: M
Population Size: 471
Sources:
Diarrhoea below serious, 9 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 471
Health Status: unhealthy
Condition: Overactive Bladder
Sex: M
Population Size: 471
Sources:
Dyspepsia below serious, 9 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 471
Health Status: unhealthy
Condition: Overactive Bladder
Sex: M
Population Size: 471
Sources:
Insomnia below serious, 9 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 471
Health Status: unhealthy
Condition: Overactive Bladder
Sex: M
Population Size: 471
Sources:
Cellulitis staphylococcal serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 471
Health Status: unhealthy
Condition: Overactive Bladder
Sex: M
Population Size: 471
Sources:
Colic renal serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 471
Health Status: unhealthy
Condition: Overactive Bladder
Sex: M
Population Size: 471
Sources:
Colitis ulcerative serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 471
Health Status: unhealthy
Condition: Overactive Bladder
Sex: M
Population Size: 471
Sources:
Dysuria serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 471
Health Status: unhealthy
Condition: Overactive Bladder
Sex: M
Population Size: 471
Sources:
Genitourinary tract infection serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 471
Health Status: unhealthy
Condition: Overactive Bladder
Sex: M
Population Size: 471
Sources:
Intervertebral disc protrusion serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 471
Health Status: unhealthy
Condition: Overactive Bladder
Sex: M
Population Size: 471
Sources:
Lung neoplasm malignant serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 471
Health Status: unhealthy
Condition: Overactive Bladder
Sex: M
Population Size: 471
Sources:
Myocardial infarction serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 471
Health Status: unhealthy
Condition: Overactive Bladder
Sex: M
Population Size: 471
Sources:
Orthostatic hypotension serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 471
Health Status: unhealthy
Condition: Overactive Bladder
Sex: M
Population Size: 471
Sources:
Testicular torsion serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 471
Health Status: unhealthy
Condition: Overactive Bladder
Sex: M
Population Size: 471
Sources:
Transitional cell carcinoma serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 471
Health Status: unhealthy
Condition: Overactive Bladder
Sex: M
Population Size: 471
Sources:
Abdominal pain below serious, 10 patients
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 679
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 679
Sources:
Dyspepsia below serious, 12 patients
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 679
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 679
Sources:
Fatigue below serious, 12 patients
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 679
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 679
Sources:
Vision blurred below serious, 12 patients
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 679
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 679
Sources:
Diarrhoea below serious, 14 patients
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 679
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 679
Sources:
Urinary tract infection below serious, 15 patients
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 679
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 679
Sources:
Dry mouth below serious, 189 patients
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 679
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 679
Sources:
Constipation below serious, 37 patients
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 679
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 679
Sources:
Headache below serious, 38 patients
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 679
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 679
Sources:
Dysuria below serious, 4 patients
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 679
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 679
Sources:
Vomiting below serious, 7 patients
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 679
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 679
Sources:
Cough below serious, 8 patients
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 679
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 679
Sources:
Dizziness below serious, 8 patients
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 679
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 679
Sources:
Hypertension below serious, 8 patients
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 679
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 679
Sources:
Abdominal pain upper below serious, 9 patients
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 679
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 679
Sources:
Abdominal pain serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 679
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 679
Sources:
Anaemia iron deficiency serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 679
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 679
Sources:
Appendicitis perforated serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 679
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 679
Sources:
Bronchiectasis serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 679
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 679
Sources:
Haemorrhage intracranial serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 679
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 679
Sources:
Haemorrhage uterine serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 679
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 679
Sources:
Hepatic neoplasm malignant serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 679
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 679
Sources:
Hypertensive heart disease serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 679
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 679
Sources:
Intervertebral disc protrusion serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 679
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 679
Sources:
Myocardial ischaemia serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 679
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 679
Sources:
Prostate cancer serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 679
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 679
Sources:
Rectal haemorrhage serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 679
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 679
Sources:
Suicidal behaviour serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 679
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 679
Sources:
Traumatic brain injury serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 679
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 679
Sources:
Upper limb fracture serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 679
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 679
Sources:
Urinary incontinence serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 679
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 679
Sources:
Acute sinusitis below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Amnesia below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Arthritis below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Basal cell carcinoma below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Blood glucose decreased below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Bronchitis below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Bursitis below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Chronic obstructive pulmonary disease below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Colitis below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Dermatitis contact below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Diverticulitis below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Dysphagia below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Dyspnoea below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Eczema below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Epistaxis below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Feeling abnormal below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Flushing below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Foot fracture below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Gait disturbance below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Gastritis below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Gastroenteritis viral below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Generalised pruritus below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Haematuria below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Haemorrhoids below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Hyperlipidaemia below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Hypertriglyceridaemia below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Hypothyroidism below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Lethargy below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Lip dry below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Memory impairment below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Muscle injury below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Muscular weakness below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Myositis below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Neck pain below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Nephrolithiasis below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Nerve compression below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Oedema below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Otorrhoea below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Paraesthesia below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Periorbital haematoma below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Pharyngitis streptococcal below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Pica below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Pneumonia primary atypical below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Polydipsia below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Polyuria below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Procedural pain below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Rectal prolapse below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Stomatitis below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Syncope below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Throat irritation below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Tooth infection below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Tremor below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Urinary incontinence below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Urine flow decreased below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Urine output decreased below serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Headache below serious, 11 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Constipation below serious, 15 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Abdominal pain upper below serious, 2 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Asthenia below serious, 2 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Blood pressure increased below serious, 2 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Cystitis below serious, 2 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Depression below serious, 2 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Dysphonia below serious, 2 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Dysuria below serious, 2 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Gastroenteritis below serious, 2 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Gastrooesophageal reflux disease below serious, 2 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Herpes zoster below serious, 2 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Muscle spasms below serious, 2 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Muscle strain below serious, 2 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Myalgia below serious, 2 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Pain in extremity below serious, 2 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Rhinorrhoea below serious, 2 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Type 2 diabetes mellitus below serious, 2 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Urinary hesitation below serious, 2 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Arthralgia below serious, 3 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Dry throat below serious, 3 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Flank pain below serious, 3 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Hypertension below serious, 3 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Nasal congestion below serious, 3 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Nasal dryness below serious, 3 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Oropharyngeal pain below serious, 3 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Urinary retention below serious, 3 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Abdominal pain below serious, 4 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Vision blurred below serious, 4 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Dyspepsia below serious, 5 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Fatigue below serious, 5 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Insomnia below serious, 5 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Upper respiratory tract infection below serious, 5 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Dizziness below serious, 6 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Dry eye below serious, 9 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Urinary tract infection below serious, 9 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Dry mouth below serious, 98 patients
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Ankle fracture serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Diabetic ketoacidosis serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Fall serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Hip fracture serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Lymphoma serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Renal failure acute serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Septic arthritis staphylococcal serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Tibia fracture serious, 1 patient
8 mg 1 times / day steady, oral (max)
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 463
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 463
Sources:
Constipation below serious, 12 patients
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 308
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 308
Sources:
Vision blurred below serious, 3 patients
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 308
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 308
Sources:
Dry mouth below serious, 51 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 308
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 308
Sources:
Dyspepsia below serious, 6 patients
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 308
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 308
Sources:
Angina pectoris serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 308
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 308
Sources:
Chronic obstructive pulmonary disease serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 308
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 308
Sources:
Hypertension serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 308
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 308
Sources:
Myocardial infarction serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 308
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 308
Sources:
Prostate cancer serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 308
Health Status: unhealthy
Condition: Overactive Bladder
Population Size: 308
Sources:
Overview

OverviewOther

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
weak
yes [Inhibition 15 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes
yes (co-administration study)
Comment: Following blockade of CYP3A4 by coadministration of the potent CYP3A4 inhibitor ketoconazoles, Cmax and AUC of the active metabolite of fesoterodine increased 2.0- and 2.3-fold, respectively, after oral administration of Toviaz to CYP2D6 extensive metabolizers. In CYP2D6 poor metabolizers, Cmax and AUC of the active metabolite of fesoterodine increased 2.1- and 2.5-fold, respectively, during coadministration of ketoconazole. Cmax and AUC were 4.5- and 5.7-fold higher, respectively, in subjects who were CYP2D6 poor metabolizers and taking ketoconazole; Following induction of CYP3A4 by coadministration of rifampicin (inducer), Cmax and AUC of the active metabolite of fesoterodine decreased by approximately 70% and 75%, respectively, after oral administration of Toviaz
Page: 38.0
yes
yes (pharmacogenomic study)
Comment: CYP2D6 PMs have values for AUC and Cmax that are about 2-fold higher that CYP2D6 EMs
Page: 38.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Gateways to clinical trials.
2002 Dec
Gateways to clinical trials.
2003 Jun
Gateways to clinical trials.
2006 Dec
Gateways to clinical trials.
2006 Jul-Aug
Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites?
2006 Nov
Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome.
2007 Dec
Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder.
2007 Oct
Overactive bladder: treatment options in primary care medicine.
2007 Sep
Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo.
2008 Apr
Toviaz approved for overactive bladder.
2008 Dec 1
Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome.
2008 Jul
Impact of fesoterodine on quality of life: pooled data from two randomized trials.
2008 Jul
Fesoterodine dose response in subjects with overactive bladder syndrome.
2008 May
Pharmacokinetic profile of fesoterodine.
2008 Nov
Comparison of fesoterodine and tolterodine in patients with overactive bladder.
2008 Nov
The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis.
2008 Sep
The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly.
2009
Fesoterodine.
2009
Fesoterodine for the treatment of overactive bladder.
2009 Aug
Muscarinic receptor antagonists for overactive bladder treatment: does one fit all?
2009 Jan
Efficacy and tolerability of fesoterodine in women with overactive bladder.
2009 Jul
A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder.
2009 Jul 22
[Anticholinergic treatment of overactive bladder syndrome. Is it all the same?].
2009 Mar
Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa.
2009 Mar
Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine.
2009 Sep
Tolterodine extended-release for overactive bladder.
2009 Sep
Bladder dysfunction in diabetes mellitus.
2010
Determination of fesoterodine in pharmaceutical formulations by using liquid chromatography-tandem mass spectrometry.
2010
Medical management of overactive bladder.
2010 Apr
Long-term safety, tolerability and efficacy of fesoterodine treatment in subjects with overactive bladder symptoms.
2010 Apr
Efficacy of fesoterodine over 24 hours in subjects with overactive bladder.
2010 Apr
The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
2010 Aug
Modeling dose-response relationships of the effects of fesoterodine in patients with overactive bladder.
2010 Aug 19
Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder.
2010 Dec
Fesoterodine fumarate.
2010 Feb
New Drugs2010, PART 1.
2010 Feb
The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing.
2010 Feb
Recent advances in management of bladder overactivity.
2010 Feb 11
Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
2010 Jan
The overlap of interstitial cystitis/painful bladder syndrome and overactive bladder.
2010 Jan-Mar
Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction.
2010 Jul
Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 phase III studies.
2010 May
Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence.
2010 Sep 14
Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects.
2011 Aug
Patents

Sample Use Guides

The recommended starting dose of Toviaz (fesoterodine fumarate) is 4 mg once daily. Based upon individual response and tolerability, the dose may be increased to 8 mg once daily. The daily dose of Toviaz should not exceed 4 mg in the following populations: • Patients with severe renal insufficiency (CLCR <30 mL/min). • Patients taking potent CYP3A4 inhibitors, such as ketoconazole, itraconazole and clarithromycin.
Route of Administration: Oral
In organ-bath studies (rat bladder) fesoterodine and 5-hydroxymethyl tolterodine, induced a concentration-dependent rightward shift of the concentration-response curve for carbachol (1 µM to 1 mM).
Name Type Language
FESOTERODINE
INN   MART.   MI   VANDF   WHO-DD  
INN  
Official Name English
FESOTERODINE [MART.]
Common Name English
FESOTERODINE [INN]
Common Name English
FESOTERODINE [VANDF]
Common Name English
FESOTERODINE [MI]
Common Name English
PROPANOIC ACID, 2-METHYL-, 2-((1R)-3-(BIS(1-METHYLETHYL)AMINO)-1-PHENYLPROPYL)-4-(HYDROXYMETHYL)PHENYL ESTER
Common Name English
FESOTERODINE [WHO-DD]
Common Name English
Classification Tree Code System Code
WHO-ATC G04BD11
Created by admin on Sat Jun 26 14:27:29 UTC 2021 , Edited by admin on Sat Jun 26 14:27:29 UTC 2021
WHO-VATC QG04BD11
Created by admin on Sat Jun 26 14:27:30 UTC 2021 , Edited by admin on Sat Jun 26 14:27:30 UTC 2021
NCI_THESAURUS C29704
Created by admin on Sat Jun 26 14:27:30 UTC 2021 , Edited by admin on Sat Jun 26 14:27:30 UTC 2021
Code System Code Type Description
RXCUI
797195
Created by admin on Sat Jun 26 14:27:30 UTC 2021 , Edited by admin on Sat Jun 26 14:27:30 UTC 2021
PRIMARY RxNorm
INN
8068
Created by admin on Sat Jun 26 14:27:29 UTC 2021 , Edited by admin on Sat Jun 26 14:27:29 UTC 2021
PRIMARY
PUBCHEM
6918558
Created by admin on Sat Jun 26 14:27:30 UTC 2021 , Edited by admin on Sat Jun 26 14:27:30 UTC 2021
PRIMARY
MERCK INDEX
M5365
Created by admin on Sat Jun 26 14:27:30 UTC 2021 , Edited by admin on Sat Jun 26 14:27:30 UTC 2021
PRIMARY Merck Index
IUPHAR
7473
Created by admin on Sat Jun 26 14:27:30 UTC 2021 , Edited by admin on Sat Jun 26 14:27:30 UTC 2021
PRIMARY
DRUG BANK
DB06702
Created by admin on Sat Jun 26 14:27:29 UTC 2021 , Edited by admin on Sat Jun 26 14:27:29 UTC 2021
PRIMARY
EPA CompTox
286930-02-7
Created by admin on Sat Jun 26 14:27:29 UTC 2021 , Edited by admin on Sat Jun 26 14:27:29 UTC 2021
PRIMARY
WIKIPEDIA
FESOTERODINE
Created by admin on Sat Jun 26 14:27:30 UTC 2021 , Edited by admin on Sat Jun 26 14:27:30 UTC 2021
PRIMARY
FDA UNII
621G617227
Created by admin on Sat Jun 26 14:27:29 UTC 2021 , Edited by admin on Sat Jun 26 14:27:29 UTC 2021
PRIMARY
CAS
286930-02-7
Created by admin on Sat Jun 26 14:27:29 UTC 2021 , Edited by admin on Sat Jun 26 14:27:29 UTC 2021
PRIMARY
EVMPD
SUB25383
Created by admin on Sat Jun 26 14:27:29 UTC 2021 , Edited by admin on Sat Jun 26 14:27:29 UTC 2021
PRIMARY
ChEMBL
CHEMBL1201764
Created by admin on Sat Jun 26 14:27:29 UTC 2021 , Edited by admin on Sat Jun 26 14:27:29 UTC 2021
PRIMARY
DRUG CENTRAL
4191
Created by admin on Sat Jun 26 14:27:29 UTC 2021 , Edited by admin on Sat Jun 26 14:27:29 UTC 2021
PRIMARY
MESH
C526675
Created by admin on Sat Jun 26 14:27:30 UTC 2021 , Edited by admin on Sat Jun 26 14:27:30 UTC 2021
PRIMARY
LACTMED
Fesoterodine
Created by admin on Sat Jun 26 14:27:30 UTC 2021 , Edited by admin on Sat Jun 26 14:27:30 UTC 2021
PRIMARY
NCI_THESAURUS
C74138
Created by admin on Sat Jun 26 14:27:30 UTC 2021 , Edited by admin on Sat Jun 26 14:27:30 UTC 2021
PRIMARY